These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 4703127)

  • 21. Plasma cell tumors in experimental chemotherapy: consequence of dose variation on host survival and paraprotein synthesis.
    Teller MN; Bowie M; Stock CC
    J Natl Cancer Inst; 1970 Dec; 45(6):1197-203. PubMed ID: 5488064
    [No Abstract]   [Full Text] [Related]  

  • 22. [Multiple myeloma--therapeutic outline].
    Yamazaki T
    Nihon Rinsho; 1970 Mar; 28():Suppl:1010-1. PubMed ID: 5464415
    [No Abstract]   [Full Text] [Related]  

  • 23. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
    Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D
    Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cytostatic treatment of prostatic carcinoma. Evaluation study of estramustinphosphate].
    Anderes A; Arquint A; Camponovo F; Deppeler O; Doerig R; Heim H; Humbert-Droz P; Jung HP; Magaro L; Sasso M; Vischer C; Wanner J; Wegmann HJ; Ziegler E
    Schweiz Rundsch Med Prax; 1971 Sep; 60(38):1276-9. PubMed ID: 5094915
    [No Abstract]   [Full Text] [Related]  

  • 25. Cure of mice bearing advanced plasma cell tumours with aniline mustard.
    Whisson ME; Connors TA
    Nature; 1965 May; 206(985):689-91. PubMed ID: 5832853
    [No Abstract]   [Full Text] [Related]  

  • 26. Optical isomers of cysteine in the prevention of leukopenia induced by nitrogen mustard.
    WEISBERGER AS; STORAASLI JP
    J Lab Clin Med; 1954 Feb; 43(2):246-52. PubMed ID: 13130941
    [No Abstract]   [Full Text] [Related]  

  • 27. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
    Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
    Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
    [No Abstract]   [Full Text] [Related]  

  • 28. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy of multiple myeloma. Study of hospital patients: 81 cases in 16 years' observation].
    Monti G; Cereda UG; Pessina E; De Micheli N; Grisetti GC; Invernizzi F
    Minerva Med; 1983 Feb; 74(5):155-63. PubMed ID: 6828250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Association of nitrogen mustard, vincristine, methylhydrazine and prednisone in treatment of diffuse forms of Hodgkin's disease and ganglionic sarcomas].
    Goudemand M; Sautière-Habay D; Bauters F; Lerche-Habart B
    Lille Med; 1968 Dec; 13(10):1102-7. PubMed ID: 4886051
    [No Abstract]   [Full Text] [Related]  

  • 31. [Results of the clinical use of asalin].
    Kruglova GV
    Vopr Onkol; 1965; 11(10):10-6. PubMed ID: 5872964
    [No Abstract]   [Full Text] [Related]  

  • 32. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 33. [Therapeutic strategies in multiple myeloma: the future role of bendamustine].
    Goldschmidt H; Kropff M; Mügge LO; Pönisch W
    Onkologie; 2013; 36 Suppl 1():19-26. PubMed ID: 23445759
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone.
    Gobbi M; Cavo M; Savelli G; Baccarani M; Tura S
    Haematologica; 1980 Aug; 65(4):437-45. PubMed ID: 6774915
    [No Abstract]   [Full Text] [Related]  

  • 35. Alkeran and multiple myeloma.
    Med Lett Drugs Ther; 1966 Apr; 8(8):32. PubMed ID: 5913764
    [No Abstract]   [Full Text] [Related]  

  • 36. [Results of immunosuppressive treatment of visceral lupus erythematosus].
    Japa J; Kardaszewicz E
    Pol Tyg Lek; 1969 Oct; 24(40):1534-6. PubMed ID: 5365671
    [No Abstract]   [Full Text] [Related]  

  • 37. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
    Kröger N; Zabelina T; Ayuk F; Atanackovic D; Schieder H; Renges H; Zander A
    Exp Hematol; 2006 Jun; 34(6):770-5. PubMed ID: 16728282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study with a new alkylating agent (PTT-119) in lymphoid malignancies.
    Tura S; Mazza P; Gherlinzoni F; Zinzani PL; Poletti G; Visani G; Lemoli RM; Bandini G; Cavo M; Galieni P
    Haematologica; 1988; 73(6):503-8. PubMed ID: 3148513
    [No Abstract]   [Full Text] [Related]  

  • 39. [Mitomen (nitrogen mustard oxide) causing leukopenia].
    DUDIK E
    Arztl Wochensch; 1956 Mar; 11(10):215-6. PubMed ID: 13326731
    [No Abstract]   [Full Text] [Related]  

  • 40. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature.
    Prasad HK; Kaushal V; Mehta P
    Am J Hematol; 2007 Sep; 82(9):855-7. PubMed ID: 17570510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.